RARA CRAFT DATABASE for FDA Medical Devices

FDA Device Decisions, January 2026: A Liquid Embolic for Chronic Subdural Hematoma, Two De Novo Grants and Two Original PMAs

日本語版

The January 2026 decision with the most clinical interest is an original PMA: SQUID Liquid Embolic Agent (P250009), approved for embolizing the middle meningeal artery as an adjunct to usual care in symptomatic chronic subdural hematoma. In the randomized trial behind the approval, treatment failure at 180 days was lower with SQUID than with usual care alone.

The same month produced a De Novo classified into Class I and exempted from 510(k): the Sana Device (DEN250005), which uses light and sound stimulation to relieve neuropathic pain.

Counting records held in RA Craft Database (decisions through August 31, 2026, tallied October 6), FDA cleared 236 510(k)s in January 2026, granted 2 De Novo requests and approved 2 original PMAs. These counts have not been reconciled with FDA's own figures. The site holds 510(k), De Novo and PMA records from 2015 onward, and counts for past months can change as the data are updated.

Counts by pathway

January 2026 next to the previous month and the same month a year earlier, with records assigned to a month by FDA decision date.

PathwayJanuary 2026December 2025January 2025
510(k)236289253
De Novo221
PMA (original)2102
PMA supplement134208148

Records held in RA Craft Database, decisions through August 31, 2026.

510(k) clearances were 53 fewer than in December and below January 2025 (253). Original PMAs fell from 10 in December to 2.

The busiest product codes

January's 510(k)s spread across 156 product codes. GEI (electrosurgical, cutting & coagulation & accessories) led with 6, followed by INI (vehicle, motorized 3-wheeled), NHA (abutment, implant, dental, endosseous), ODP (intervertebral fusion device with bone graft, cervical), PHX (shoulder prosthesis, reverse configuration) and QIH (automated radiological image processing software) with 5 each. A single 510(k) can carry more than one product code, so per-code counts can add up to more than the number of submissions. If your code is on the list, enter it in the Product Code field on Search to see the records sorted by decision date.

De Novo: two classifications, one of them Class I

January's two De Novo grants, with the classification names and regulation numbers from each Classification Order:

  • VitaSmart Hypothermic Oxygenated Perfusion System (DEN250009, Bridge to Life, Ltd.): Hypothermic machine perfusion system and accessories for orthotopic liver transplant (21 CFR 876.5881), Class II
  • Sana Device (DEN250005, Sana Health): Audio-visual stimulator for pain relief (21 CFR 890.5775), Class I

"21 CFR" refers to Title 21 of the Code of Federal Regulations, where FDA's regulations are codified.

VitaSmart provides hypothermic oxygenated perfusion of donor livers after static cold storage. Its indications spell out donor criteria, such as donors after brain death aged 65 or younger, and donors after circulatory death aged 55 or younger with functional warm ischemic time of 18 minutes or less.

The Sana Device was placed in Class I and exempted from 510(k). Devices of the same type can now go to market without a 510(k), within the limits of the exemption.

Original PMAs: two approvals

  • MAGiC Ablation Catheter (P240014, Stereotaxis, Inc.): a radiofrequency ablation catheter steered by robotic magnetic navigation, for supraventricular tachycardia in patients with congenital heart disease whose anatomy limits manual catheter access (product code LPB)
  • SQUID Liquid Embolic Agent (P250009, Balt USA, LLC): a liquid embolic for middle meningeal artery embolization in chronic subdural hematoma (SGU)

Both approval orders require post-approval studies: for MAGiC, a study of at least 40 adults with congenital heart disease; for SQUID, a real-world study of 500 patients, 250 managed surgically and 250 non-surgically. January also brought 134 PMA supplements, which cover changes to already approved PMA devices among other things.

Three devices worth a closer read

1. SQUID Liquid Embolic Agent (P250009, PMA). For symptomatic chronic subdural hematomas 10 mm or thicker where a neurosurgeon judges intervention necessary, SQUID embolizes the middle meningeal artery on top of usual care. According to the Summary of Safety and Effectiveness Data (SSED) that FDA published with the approval, in the multicenter randomized STEM trial the composite treatment failure rate at 180 days was 16.2% with SQUID and 38.2% with usual care alone. The embolic goes into the artery feeding the hematoma, not into the hematoma itself.

2. Sana Device (DEN250005, De Novo). Light stimuli to the eyes and sound stimuli to the ears, for temporary relief of neuropathic pain in adults 18 and older, as an adjunct to other therapy at home or in the clinic. It is a prescription device, but FDA set no special controls and found general controls sufficient.

3. VitaSmart Hypothermic Oxygenated Perfusion System (DEN250009, De Novo). Its ten special controls include clinical performance testing and human factors validation, and a training program so that users can correctly prepare, perfuse and monitor the organ. Where the user's technique shapes the outcome, training can become a condition of the classification.

Compare the three devices

Open P250009, DEN250005 and DEN250009, star (☆) each one, tick "Compare" on all three in My Workspace and press "3 selected for comparison". The comparison table puts their Indications for Use side by side. Before relying on any of this, open "FDA Record" and "Summary PDF" on each record and read the source.

Note: months are assigned by FDA decision date, and counts can change as the data are updated each month.

RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.

← All articles